



ASX ANNOUNCEMENT

Lumos Diagnostics Investor Roadshow Webinar

Melbourne, VIC. (15th September 2023) - Lumos Diagnostics (ASX:LDX, “Lumos” or the “Company”) today announces that CEO Doug Ward and CFO Barrie Lambert will be meeting with investors in Australia during the week commencing 18th September 2023. As part of this roadshow, the Company will be hosting a webinar based on the presentation that it will be providing in these meetings.

Details for the webinar that the Company will host in relation to this roadshow are provided below.

Webinar

Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) is pleased to invite shareholders and other interested parties to a Shareholder Webinar hosted by CEO Doug Ward and CFO Barrie Lambert to discuss the FY2023 full year results and provide an update on the Company’s activities.

The webinar will be held on **Monday 18 September 2023 at 11.00am AEST**.

For the Q&A session, investors are invited to send questions prior to the webinar to:

matt@nwrcommunications.com.au

Register for the webinar at the link below:

https://us02web.zoom.us/webinar/register/WN_-XBVCNNqRtuatUhSt6qRGQ

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those who would prefer to join by phone. A recording will be available at the above link shortly after the conclusion of the live session.

###

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or call +1 941-556-1850.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598